Abstract
Primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD) stays to be one of the Czech health care priorities. The ABC of ASCVD prevention is healthy life style and LDL-cholesterol (ch), the most causal risk factor among all, reduction.
To reach the new ambicious LDL-ch aims is impossible by only statin monotherapy. Combination of statin and ezetimibe has got the highest class of recommendation.
That fixed combination is very effective, well tolerated and improves therapy adherence. It is eligible for all patients with very high or high global cardiovascular risk.
The advantages of atorvastatin and ezetimibe fixed combination in patients after acute coronary syndrome and /or in patients with renal failure are mentioned. (C) 2020 SOLEN s.r.o.. All rights reserved.